TY - JOUR
T1 - BRG1 loss predisposes lung cancers to replicative stress and ATR dependency
AU - Gupta, Manav
AU - Concepcion, Carla P.
AU - Fahey, Caroline G.
AU - Keshishian, Hasmik
AU - Bhutkar, Arjun
AU - Brainson, Christine F.
AU - Sanchez-Rivera, Francisco J.
AU - Pessina, Patrizia
AU - Kim, Jonathan Y.
AU - Simoneau, Antoine
AU - Paschini, Margherita
AU - Beytagh, Mary C.
AU - Stanclift, Caroline R.
AU - Schenone, Monica
AU - Mani, D. R.
AU - Li, Chendi
AU - Oh, Audris
AU - Li, Fei
AU - Hu, Hai
AU - Karatza, Angeliki
AU - Bronson, Roderick T.
AU - Shaw, Alice T.
AU - Hata, Aaron N.
AU - Wong, Kwok Kin
AU - Zou, Lee
AU - Carr, Steven A.
AU - Jacks, Tyler
AU - Kim, Carla F.
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/9/15
Y1 - 2020/9/15
N2 - Inactivation of SMARCA4/BRG1, the core ATPase subunit of mammalian SWI/SNF complexes, occurs at very high frequencies in non-small cell lung cancers (NSCLC). There are no targeted therapies for this subset of lung cancers, nor is it known how mutations in BRG1 contribute to lung cancer progression. Using a combination of gain- and loss-of-function approaches, we demonstrate that deletion of BRG1 in lung cancer leads to activation of replication stress responses. Single-molecule assessment of replication fork dynamics in BRG1-deficient cells revealed increased origin firing mediated by the prelicensing protein, CDC6. Quantitative mass spectrometry and coimmunoprecipitation assays showed that BRG1-containing SWI/SNF complexes interact with RPA complexes. Finally, BRG1-deficient lung cancers were sensitive to pharmacologic inhibition of ATR. These findings provide novel mechanistic insight into BRG1-mutant lung cancers and suggest that their dependency on ATR can be leveraged therapeutically and potentially expanded to BRG1-mutant cancers in other tissues.
AB - Inactivation of SMARCA4/BRG1, the core ATPase subunit of mammalian SWI/SNF complexes, occurs at very high frequencies in non-small cell lung cancers (NSCLC). There are no targeted therapies for this subset of lung cancers, nor is it known how mutations in BRG1 contribute to lung cancer progression. Using a combination of gain- and loss-of-function approaches, we demonstrate that deletion of BRG1 in lung cancer leads to activation of replication stress responses. Single-molecule assessment of replication fork dynamics in BRG1-deficient cells revealed increased origin firing mediated by the prelicensing protein, CDC6. Quantitative mass spectrometry and coimmunoprecipitation assays showed that BRG1-containing SWI/SNF complexes interact with RPA complexes. Finally, BRG1-deficient lung cancers were sensitive to pharmacologic inhibition of ATR. These findings provide novel mechanistic insight into BRG1-mutant lung cancers and suggest that their dependency on ATR can be leveraged therapeutically and potentially expanded to BRG1-mutant cancers in other tissues.
UR - http://www.scopus.com/inward/record.url?scp=85097607302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097607302&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-1744
DO - 10.1158/0008-5472.CAN-20-1744
M3 - Article
C2 - 32690724
AN - SCOPUS:85097607302
SN - 0008-5472
VL - 80
SP - 3841
EP - 3854
JO - Cancer Research
JF - Cancer Research
IS - 18
ER -